SCHEMBL7211477

SCHEMBL7211477

O=S(=O)(NCc1ccccc1)c1cccs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
HPGD P15428 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
KEAP1 Q14145 1/20 0.58
ALDH1A1 P00352 2/20 0.57
TSHR P16473 1/20 0.55
CA12 O43570 1/20 0.53
CA2 P00918 1/20 0.53
CA7 P43166 1/20 0.53
CA14 Q9ULX7 1/20 0.53
KDM4E B2RXH2 1/20 0.52
RAB9A P51151 1/20 0.52
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25547148 0.85 MEN1 (0.62) CYP2D6CYP2C9CYP2C19HPGDL3MBTL1
SCHEMBL7217749 0.83 CYP2D6 (0.72) CYP2D6CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL28204596 0.82 TP53 (0.64) CYP2D6CYP2C9CYP2C19ALDH1A1TSHR
SCHEMBL6121906 0.81 CYP2D6 (0.68) CYP2D6CYP2C9CYP2C19HPGDL3MBTL1
SCHEMBL498795 0.79 KEAP1 (0.46) HPGDL3MBTL1KEAP1CA12CA2
SCHEMBL17009273 0.78 PKM (0.69) CYP2D6CYP2C9CYP2C19ALDH1A1PKM
Ammonia Solution, Strong SCHEMBL28203960 0.77 PKM (0.68) ALDH1A1PKM
SCHEMBL7571190 0.77 CYP2D6 (0.62) CYP2D6CYP2C9CYP2C19HPGDL3MBTL1
SCHEMBL5655445 0.77 CYP2D6 (0.72) CYP2D6CYP2C9CYP2C19HPGDL3MBTL1
SCHEMBL28588864 0.77 CYP2D6 (0.72) CYP2D6CYP2C9CYP2C19HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021039824-A1 RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR 国立大学法人 岡山大学 2021-03-04 WO disclosed
US-6613804-B2 Treatment of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock ENCYSIVE PHARMACEUTICALS, INC. 2003-09-02 US disclosed
US-6342610-B2 COMPOUNDS SUCH AS N-(4-BROMO-3-METHYL-5-ISOXAZOLYL)-2-N-BENZYLBENZO(B)THIOPHENE-3-SUFONAMIDE ADMINISTERED AS ENDOTHELIN PEPTIDE RECEPTOR ANTAGONISTS TEXAS BIOTECHNOLOGY CORP. 2002-01-29 US disclosed
US-6331637-B1 N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin TEXAS BIOTECHNOLOGY CORPORATION 2001-12-18 US disclosed
EP-0819125-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1998-01-21 EP disclosed
WO-1996031492-A1 THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1996-10-10 WO disclosed